🔗 Share this article

As the United States continues making unprecedented revisions to its immunization schedules, an unexpected name has emerged somewhat surprisingly: Høeg, a US-based sports physician and epidemiologist who rose to prominence by questioning coronavirus vaccines throughout the pandemic and has zeroed in on possible fatalities following COVID-19 vaccination in her short position at the US Food and Drug Administration (FDA).

Proposed Shifts to Pediatric Immunization Program

Public health authorities were set to announce radical revisions to the pediatric immunization program in December, aligning the US with Denmark’s immunization schedule, sources say – a substantial departure that would put the US at odds with much of the international standard with insufficient data for improved outcomes. The announcement has been postponed until the next year.

Instead of the director of the vaccine center, Tracy Beth Høeg is set to address the audience at the gathering. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the division this year.

A New Direction at the Agency

This interim role may indicate a closer partnership between the pharmaceutical and biologics branches as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it signals a increased emphasis upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for halting specific childhood shot schedules in the US in order to be more similar to Denmark's approach, a society with comprehensive healthcare and a population about the size of the state of Wisconsin.

In her initial public appearances, she has kept her attention on vaccination policy – usually the domain of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Questions Over Background

Høeg has no apparent background in pharmaceutical research, approval processes or leadership, which has been standard for previous heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the commissioner and the vaccine center since March.

“She appears not to have the requisite experience” for leading the drug-regulation department, remarked a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She has no expertise in managing a major agency. She lacks background in industry regulation.”

Past directors of the center would “be deeply familiar with laws and regulations and the research of medication creation”, commented a former acting FDA commissioner. “Clearly, she doesn’t have the sort of resume that prior appointees who ran the center have had.”

This division has an immense workload at the FDA, Woodcock stated.

“The public just focuses on the innovative therapies, but the off-patent medication office clears thousands of generic drugs. There is also a biosimilars division, non-prescription drug unit and so forth, and all of those have to be managed,” she explained. “The area you overlook, that is the part that I always told people is going to cause problems.”

Additionally, a substantial leadership element to the role, which supervises over 5,000 employees. “It is a enormous leadership role, if you execute it properly,” Woodcock said.

Response and Disputed Policies

When asked about questions about Høeg’s fitness for the role and whether this assignment indicates more teamwork among regulatory chiefs on vaccines, a representative responded that the “concerns rely on inaccurate premises”.

“This background matches the functions of her job,” the spokesperson said, pointing to the time Høeg spent counseling the agency head on “medication safety and approval science, including computerized risk analysis and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s controversial expedited review system, a contentious rapid drug-approval program that apparently concerned her predecessors. “How are these drugs being chosen for this expedited pathway? Who makes the decisions?” Dr. Howard said. “There is a lot of lack of transparency happening at the agency right now.”

Overall, he remarked, “the FDA seems to be moving towards less stringent regulations of most medications, with the exception of shots.”

Public Past Work on Vaccines

Regarding immunizations, Dr. Høeg has a more documented, if troubling, history, some experts said. She authored a study using non-validated volunteer-provided data to assess the frequency of heart inflammation after Covid vaccination. She advised the Florida chief medical officer Joseph Ladapo, who allegedly have modified findings to indicate Covid vaccines are pose a greater threat than they are.

Included in her “policy goals” for the new federal leadership included changing rules for novel immunizations and ending “non-essential” immunizations, she said after the election on a online show. At the FDA, Dr. Høeg has according to sources proposed barring teenage boys from getting COVID-19 vaccines.

“She is an thorough ideologue who commences with her conclusions and tailors the evidence to accommodate the evidence in a extremely disingenuous, fraudulent way,” Dr. Howard stated.

Gaining Influence and a “Campaign of Retribution”

Høeg joined other dissenters, {like|